SEFFIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Seffin, and when can generic versions of Seffin launch?
Seffin is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in SEFFIN is cephalothin sodium. There are seven drug master file entries for this compound. Additional details are available on the cephalothin sodium profile page.
US Patents and Regulatory Information for SEFFIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | SEFFIN | cephalothin sodium | INJECTABLE;INJECTION | 062435-001 | Nov 15, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glaxosmithkline | SEFFIN | cephalothin sodium | INJECTABLE;INJECTION | 062435-002 | Nov 15, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glaxosmithkline | SEFFIN | cephalothin sodium | INJECTABLE;INJECTION | 062435-003 | Nov 15, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
